Literature DB >> 16738903

Psoriasis onset during infliximab treatment: description of two cases.

Alessandro Volpe1, Paola Caramaschi, Antonio Carletto, Sara Pieropan, Lisa Maria Bambara, Domenico Biasi.   

Abstract

The authors describe two patients with no personal or family history of psoriasis who developed psoriatic lesions during infliximab treatment: a woman affected by seronegative rheumatoid arthritis and a man affected by ankylosing spondylitis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16738903     DOI： 10.1007/s00296-006-0144-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  20 in total

1.  Psoriasiform eruption induced by infliximab.

Authors:  María M Verea; Jesús Del Pozo; M Teresa Yebra-Pimentel; Angeles Porta; Eduardo Fonseca
Journal:  Ann Pharmacother       Date:  2004-01       Impact factor: 3.154

2.  Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern.

Authors:  Gloria Vergara; Juan Francisco Silvestre; Isabel Betlloch; Paloma Vela; María Pilar Albares; José Carlos Pascual
Journal:  Arch Dermatol       Date:  2002-09

3.  Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases.

Authors:  O Dereure; B Guillot; C Jorgensen; J-D Cohen; B Combes; J-J Guilhou
Journal:  Br J Dermatol       Date:  2004-08       Impact factor: 9.302

4.  Anti-TNF-alpha therapy for sight threatening uveitis.

Authors:  E W Lindstedt; G S Baarsma; R W A M Kuijpers; P M van Hagen
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Drug-induced systemic lupus erythematosus associated with etanercept therapy.

Authors:  Najia Shakoor; Margaret Michalska; Charlotte A Harris; Joel A Block
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

Review 7.  Drug-induced psoriasis. Recognition and management.

Authors:  N Tsankov; I Angelova; J Kazandjieva
Journal:  Am J Clin Dermatol       Date:  2000 May-Jun       Impact factor: 7.403

8.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.

Authors:  Alice B Gottlieb; Robert Evans; Shu Li; Lisa T Dooley; Cynthia A Guzzo; Daniel Baker; Mohan Bala; Colleen W Marano; Alan Menter
Journal:  J Am Acad Dermatol       Date:  2004-10       Impact factor: 11.527

9.  Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

Authors:  Martin Aringer; Winfried B Graninger; Günter Steiner; Josef S Smolen
Journal:  Arthritis Rheum       Date:  2004-10

10.  Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.

Authors:  A P Cope; M Londei; N R Chu; S B Cohen; M J Elliott; F M Brennan; R N Maini; M Feldmann
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808
View more
  2 in total

1.  Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated.

Authors:  Hua-Xin Liao; Xi Chen; Supriya Munshaw; Ruijun Zhang; Dawn J Marshall; Nathan Vandergrift; John F Whitesides; Xiaozhi Lu; Jae-Sung Yu; Kwan-Ki Hwang; Feng Gao; Martin Markowitz; Sonya L Heath; Katharine J Bar; Paul A Goepfert; David C Montefiori; George C Shaw; S Munir Alam; David M Margolis; Thomas N Denny; Scott D Boyd; Eleanor Marshal; Michael Egholm; Birgitte B Simen; Bozena Hanczaruk; Andrew Z Fire; Gerald Voss; Garnett Kelsoe; Georgia D Tomaras; M Anthony Moody; Thomas B Kepler; Barton F Haynes
Journal:  J Exp Med       Date:  2011-10-10       Impact factor: 14.307

2.  The changing face of spondyloarthropathies under TNF α blockade.

Authors:  Ori Elkayam; Irena Litinsky; David Levartovsky; Dan Caspi
Journal:  Open Rheumatol J       Date:  2008-11-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.